A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma

Inclusion Criteria:

• The subjects voluntarily joined the study, signed the informed consent, and thecompliance was good;

• Age: 18 years old ≤ age (when signing the informed consent) ≤75 years old; Easterncooperative oncology group (ECOG) score: 0-2; Expected survival of more than 3months;

• Histologically confirmed B-cell lymphomas of the following types that meet the 2022World Health Organization (WHO) diagnostic criteria:

1. Relapsed/refractory indolent B-cell lymphoma

2. Diffuse large B cell lymphoma（DLBCL）

• Previous treatment: Relapsed/refractory inert B-cell lymphoma: have received atleast one previous line of systemic standard therapy

• Have at least one measurable lesion.

• The main organs function well.

• Female subjects of reproductive age should agree to use contraception (such as Iuds,contraceptives, or condoms) during the study period and for 6 months after the endof the study; Have a negative serum pregnancy test within 7 days prior to studyenrollment and must be a non-lactating subject; Male subjects should agree to useavoidance during the study period and for 6 months after the end of the studyperiod.

Exclusion Criteria:

• Have had or are currently suffering from other malignant tumors within 3 years priorto the first medication.

• Known or suspected central nervous system (CNS) aggression.

• Relapsed/refractory inert B-cell lymphoma: previous allogeneic hematopoietic stemcell transplantation, or autologous hematopoietic stem cell transplantation within 3months before the first treatment;

• Recurrent/refractory indolent B-cell lymphoma: toxic reactions that do not return to ≤ National Cancer Institute standard for common toxic reactions (NCI-CTC) AE Grade 1due to any previous treatment, excluding hair loss and fatigue;

• Have multiple factors that affect oral drug absorption (such as inability toswallow, chronic diarrhea, and intestinal obstruction);

• Received major surgical treatment or significant traumatic injury within 28 daysbefore the start of study treatment;

• Hyperkinetic/venous thrombosis events occurred within 6 months before the firstmedication;

• Have a history of psychotropic drug abuse and can not quit or have mental disorders;

• Subjects with any severe and/or uncontrolled disease;

• Received live vaccine or messenger ribonucleic acid (mRNA) vaccine within 4 weeksbefore the first dose, or planned to receive live vaccine or mRNA vaccine during thestudy;

• Participated in clinical trials of other antitumor drugs within 4 weeks before thefirst medication;

• Subjects who, in the judgment of the investigator, have concomitant diseases thatseriously endanger the safety of the subjects or affect the completion of the study,or subjects who are not suitable for enrollment for other reasons.